Your session is about to expire
← Back to Search
Necitumumab + Chemotherapy for Non-Small Cell Lung Cancer (SQUIRE Trial)
SQUIRE Trial Summary
This trial is testing a new drug to see if it's more effective than standard chemotherapy for lung cancer.
SQUIRE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 633 Patients • NCT00982111SQUIRE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- If you are a woman who could become pregnant, you need to have a negative pregnancy test within a week before joining the study.You have a condition called superior vena cava syndrome that makes it unsafe for you to receive fluids.You have had chemotherapy for advanced lung cancer, unless your last treatment was at least 1 year ago as part of a previous treatment plan.You have had radiation treatment to your chest in the past 12 weeks, except for palliative treatment to bone lesions.You have brain tumors that are causing symptoms or need ongoing treatment with medication. If you had brain tumors in the past but they are not causing symptoms now, you may be eligible.You currently have serious heart problems or uncontrolled congestive heart failure.You need to have stored tumor tissue that can be tested for specific gene mutations and gene copy number.You have a type of lung cancer called nonsquamous NSCLC, which includes adenocarcinoma or large cell types.Your kidneys work well enough.You have a current or ongoing infection that needs antibiotics, including tuberculosis or HIV.Your liver is working properly.You have been diagnosed with a specific type of lung cancer called squamous non-small cell lung cancer.You have a history of major brain or mental health conditions like dementia, seizures, or bipolar disorder.You have excessive fluid buildup that needs to be drained often.You had a heart attack within the past 6 months.You have a history of using drugs in a harmful way.You have another type of cancer that is not skin cancer or pre-cervical cancer that is not under control. If you had a different cancer before, it must have been at least 3 years since you were treated for it.You have cancer that can be measured or seen on scans according to specific guidelines. If your cancer cannot be measured, you may not be eligible.You have advanced (Stage IV) disease when starting the study.Your blood is working properly.You have moderate to severe peripheral neuropathy according to the NCI-CTCAE Version 3.0 grading system.You have received treatments targeting specific proteins related to cancer growth in the past.
- Group 1: Necitumumab + Gemcitabine + Cisplatin
- Group 2: Gemcitabine + Cisplatin
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What other scientific tests have been done that included Necitumumab?
"Necitumumab is being researched in 1012 different active studies, with 347 of those studies taking place during Phase 3. Necitumumab clinical trials are located all over the world, but especially in Shanghai, China."
Are patients currently being enrolled in this trial?
"Right now, this study isn't looking for any new participants. It was first posted on January 7th, 2010 and updated February 4th, 2022. If you're interested in other trials, 2095 studies are currently recruiting patients with lung cancer and 1012 Necitumumab trials have open enrolment."
For what purpose is Necitumumab most commonly prescribed?
"Necitumumab is not only indicated for the treatment of neoplasm metastasis, but also useful in treating other conditions like urinary bladder and advanced testicular cancer."
What is the FDA's decision on Necitumumab?
"There is both anecdotal and scientific evidence supporting the safety of Necitumumab, so it received a score of 3."
How many individuals are enrolled in this clinical trial?
"Presently, this trial is not seeking any more participants. It was first posted on January 7th 2010 and received its last edit on February 4th 2022. However, there are 2095 other studies involving lung cancer that are actively recruiting patients as well as 1012 for Necitumumab."
In how many different medical clinics is this trial being run today?
"Currently, this clinical trial is enrolling patients from a total of 18 sites. While Saskatoon, Baltimore and Sacramento are some of the locations, it is worth investigating the other 14 to see if one suits you better in order to minimize travel time commitments."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger